Literature DB >> 9030960

Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications.

R Garand1, N Robillard.   

Abstract

Immunophenotypic characterization of leukemic cells has become essential for the diagnosis of acute leukemias (AL) and chronic lymphoproliferative disorders (CLPD). Immunophenotyping allows to classify AL according to (i) lineage assignment of the leukemic clone based on the degree of specificity (or "score") of expressed markers, (ii) the differentiation level of the clone and (iii) the presence of irrelevant markers. In addition, some rare AL subtypes may be identified, such as M0, M6 "variant" and M7 FAB types, as well as "biphenotypic" (hybrid) AL. Finally particular immunophenotypic profiles are of pronostic value or associated with specific cytogenetic abnormalities. In leukemic phase CLPD setting, some circulating lymphoid cell immunophenotypic profiles are strongly correlated with morphology as defined by the FAB and REAL classifications. In addition, some marker expressions are of pronostic value. However, proper choices of sample nature, monoclonal antibodies and immunophenotyping methods are essential to improve quality, reliability and reproducibility of the results and must be carefully controlled in and between laboratories.

Entities:  

Mesh:

Year:  1996        PMID: 9030960     DOI: 10.1007/s00282-996-0471-4

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  4 in total

1.  Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia.

Authors:  Eloisa Jantus Lewintre; Cristina Reinoso Martín; Carlos García Ballesteros; David Montaner; Rosa Farrás Rivera; José Ramón Mayans; Javier García-Conde
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

Review 2.  Metabolomics Applications in Precision Medicine: An Oncological Perspective.

Authors:  Leonor Puchades-Carrasco; Antonio Pineda-Lucena
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

3.  Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).

Authors:  Yannan Jia; Dong Lin; Zhe Wang; Chengwen Li; Huijun Wang; Jianxiang Wang; Yingchang Mi
Journal:  Diagn Pathol       Date:  2022-10-05       Impact factor: 3.196

4.  In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase.

Authors:  Fankai Meng; Wen Zeng; Lifang Huang; Shuang Qin; Ningning Miao; Hanying Sun; Chunrui Li
Journal:  Oncol Lett       Date:  2014-01-02       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.